litlas
Log inCreate account

Federico Cappuzzo

Active 1996–2025

161
Papers
43,654
Citations
88
h-index
151
i10-index

Citations

Citations per year for Federico Cappuzzo1976: 4 citations1984: 1 citations1994: 1 citations1996: 2 citations1998: 1 citations1999: 3 citations2000: 7 citations2001: 7 citations2002: 6 citations2003: 4 citations2004: 21 citations2005: 74 citations2006: 159 citations2007: 174 citations2008: 264 citations2009: 254 citations2010: 286 citations2011: 351 citations2012: 356 citations2013: 468 citations2014: 360 citations2015: 487 citations2016: 511 citations2017: 450 citations2018: 471 citations2019: 1,584 citations2020: 1,799 citations2021: 1,687 citations2022: 1,349 citations2023: 935 citations2024: 1,674 citations2025: 953 citations2026: 21 citations1977–1983: no citations, so these years are not shown1985–1993: no citations, so these years are not shown1995: no citations, so this year is not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,548 citing papers, 24% of this breakdownChina: 2,739 citing papers, 14.4% of this breakdownItaly: 1,254 citing papers, 6.6% of this breakdownJapan: 1,066 citing papers, 5.6% of this breakdownUnited Kingdom: 898 citing papers, 4.7% of this breakdownGermany: 836 citing papers, 4.4% of this breakdownFrance: 826 citing papers, 4.4% of this breakdownSpain: 747 citing papers, 3.9% of this breakdownSouth Korea: 546 citing papers, 2.9% of this breakdownCanada: 493 citing papers, 2.6% of this breakdownNetherlands: 457 citing papers, 2.4% of this breakdownSwitzerland: 445 citing papers, 2.3% of this breakdown
0%24%Other 21.8%

Institutions

Fields

  • Medicine77.3%
  • Biochemistry, Genetics and Molecular Biology17.4%
  • Immunology and Microbiology2.1%
  • Computer Science0.6%
  • Engineering0.5%
  • Materials Science0.5%
  • Other1.6%

Topics

  • Lung Cancer Treatments and Mutations14%
  • Cancer Immunotherapy and Biomarkers10%
  • Lung Cancer Research Studies7.7%
  • Lung Cancer Diagnosis and Treatment4.4%
  • Cancer Genomics and Diagnostics3.6%
  • Colorectal Cancer Treatments and Studies3.5%
  • Other56.8%

Coauthors

All papers

Open in search
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 cited by 3,753

  2. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    Authors: Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo - The Lancet Oncology 2019 cited by 1,681

  3. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

    Authors: Antonio Passaro, Jing Wang, Yan Wang, S.-H. Lee, Barbara Melosky, Jin‐Yuan Shih, Jing Wang, K. Azuma, Óscar Juan, Manuel Cobo, Enriqueta Felip, Nicolas Girard, Alexis B. Cortot, Raffaele Califano, Federico Cappuzzo, Scott Owen, Sanjay Popat, Ju Le Tan, Jorge Salinas, Pascale Tomasini, Ryan D. Gentzler, William N. William, Karen L. Reckamp, Toshiaki Takahashi, Sandip Ganguly, Dariusz M. Kowalski, Alessandra Bearz, Melanie Mackean, P. Barala, Ariel B. Bourla, Angela Girvin, James Greger, Dawn Millington, Monica Withelder, John Xie, Tao Sun, Shalin Shah, B. Diorio, Roland E. Knoblauch, Joshua Bauml, Rosario García Campelo, Byoung Chul Cho - Annals of Oncology 2023 cited by 396

  4. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    Authors: Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall - New England Journal of Medicine 2014 cited by 3,213

  5. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Authors: Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne - Science 2007 cited by 4,485

  6. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

    Authors: Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Shengchun Kong, Anthony Lee, Shelley Coleman, Wei Zou, Mark L. McCleland, Geetha Shankar, Martin Reck - Journal of Thoracic Oncology 2021 cited by 523

  7. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

    Authors: Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski - The Lancet Respiratory Medicine 2019 cited by 939

  8. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

    Authors: Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, J. Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi Hines, Jacqueline V. Aredo, Michael J. Dennis, Turja Chakrabarti, Susan C. Scott, Paolo Bironzo, Matthias Scheffler, Petros Christopoulos, Albrecht Stenzinger, Jonathan W. Riess, So Yeon Kim, Sarah B. Goldberg, Mingjia Li, Qi Wang, Yun Qing, Ying Ni, Minh Truong, Richard Lee, Biagio Ricciuti, Joao V. Alessi, Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R. Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A. Vaporciyan, George R. Blumenschein, Jianjun Zhang, Dwight H. Owen, Collin M. Blakely, Giannis Mountzios, Catherine A. Shu, Christine M. Bestvina, Marina Chiara Garassino, Kristen A. Marrone, Jhanelle E. Gray, Sandip Pravin Patel, Amy L. Cummings, Heather A. Wakelee, Juergen Wolf, Giorgio V. Scagliotti, Federico Cappuzzo, Fabrice Barlési, Pradnya D. Patil, Leylah Drusbosky, Don L. Gibbons, Funda Meric‐Bernstam, J. Jack Lee, John V. Heymach, David S. Hong, Rebecca S. Heist, Mark M. Awad, Ferdinandos Skoulidis - Cancer Discovery 2023 cited by 181

  9. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

    Authors: Fiona Blackhall, Kevin Jao, Laurent Greillier, Byoung Chul Cho, Konstantin Penkov, Noemı́ Reguart, Margarita Majem, Kristiaan Nackaerts, Konstantinos Syrigos, Karin Holmskov Hansen, Wolfgang Schuette, Jeremy Cetnar, Federico Cappuzzo, Isamu Okamoto, Mustafa Erman, Seppo W. Langer, Terufumi Kato, Harry J.M. Groen, Zhaowen Sun, Yan Luo, Poonam Tanwani, L. Caffrey, Philip Komarnitsky, Niels Reinmuth - Journal of Thoracic Oncology 2021 cited by 258

  10. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Authors: Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol - The Lancet 2014 cited by 1,308

  11. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

    Authors: Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony Mok, Gene Grant Finley, Joachim G.J.V. Aerts, Francesco Orlandi, Denis Moro‐Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodríguez‐Abreu, Wan‐Teck Lim, David M. Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bāra, Makoto Nishio - Journal of Thoracic Oncology 2021 cited by 303

  12. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Authors: Martin Peifer, Lynnette Fernandez‐Cuesta, Martin L. Sos, Julie George, Danila Seidel, Lawryn H. Kasper, Dennis Plenker, Frauke Leenders, Ruping Sun, Thomas Zander, Roopika Menon, Mirjam Koker, Ilona Dahmen, Christian Müller, Vincenzo Di Cerbo, Hans‐Ulrich Schildhaus, Janine Altmüller, Ingelore Baessmann, Christian Becker, Bram De Wilde, Jo Vandesompele, Diana Böhm, Sascha Ansén, Franziska Gabler, Ines Wilkening, Stefanie Heynck, Johannes M. Heuckmann, Xin Lü, Scott L. Carter, Kristian Cibulskis, Shantanu Banerji, Gad Getz, Kwon-Sik Park, Daniel Rauh, Christian Grütter, Matthias Fischer, Laura Pasqualucci, Gavin Wright, Zoe Wainer, Prudence A. Russell, Iver Petersen, Yuan Chen, Erich Stoelben, Corinna Ludwig, Philipp A. Schnabel, Hans Hoffmann, Thomas Muley, Michael Brockmann, Walburga Engel-Riedel, Lucia Anna Muscarella, Vito Michele Fazio, Harry J.M. Groen, Wim Timens, Hannie Sietsma, Erik Thunnissen, Egbert F. Smit, Daniëlle A.M. Heideman, Peter J.F. Snijders, Federico Cappuzzo, Claudia Ligorio, Stefania Damiani, John K. Field, Steinar Solberg, Odd Terje Brustugun, Marius Lund‐Iversen, Jörg Sänger, Joachim H. Clement, Alex Soltermann, Holger Moch, Walter Weder, Benjamin Solomon, Jean‐Charles Soria, Pierre Validire, Benjamin Besse, Élisabeth Brambilla, Christian Brambilla, Sylvie Lantuéjoul, Philippe Lorimier, Peter M. Schneider, Michael Hallek, William Pao, Matthew Meyerson, Julien Sage, Jay Shendure, Robert C. Schneider, Reinhard Büttner, Jürgen Wolf, Peter Nürnberg, Sven Perner, Lukas C. Heukamp, Paul K. Brindle, Stefan A. Haas, Roman K. Thomas - Nature Genetics 2012 cited by 1,418

  13. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    Authors: Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski - Journal of Thoracic Oncology 2020 cited by 607

  14. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Authors: Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T. Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent‐Puig, Frédérique Penault–Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric FIORE, Alice Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar - The Lancet Oncology 2010 cited by 2,143

  15. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

    Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony Mok, Martin Reck, Gene Grant Finley, Monika Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard West - JAMA Oncology 2023 cited by 186

  16. New promises and challenges in the treatment of advanced non-small-cell lung cancer

    Authors: May‐Lucie Meyer, Bailey G. Fitzgerald, Luis Paz‐Ares, Federico Cappuzzo, Pasi A. Jänne, Solange Peters, Fred R. Hirsch - The Lancet 2024 cited by 367

  17. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

    Authors: Barbara Melosky, Kato Kambartel, Maik Häntschel, M Bennetts, Dana J. Nickens, Julia Brinkmann, Antonin Kayser, Michael Moran, Federico Cappuzzo - Molecular Diagnosis & Therapy 2021 cited by 235

  18. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

    Authors: Siow Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz M. Kowalski, Aleksandra Szczęsna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano, Diego Cortinovis, Anh T. Le, Dingzhi Huang, Geoffrey Liu, Federico Cappuzzo, Jessica Reyes Contreras, Martin Reck, Ramón Palmero, Milena Perez Mak, Youyou Hu, Stefanie Morris, Elen Höglander, Mary M. Connors, Alice M. Biggane, Hans Kristian Moen Vollan, Solange Peters - The Lancet 2023 cited by 158

  19. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

    Authors: Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, Taroh Satoh, Federico Cappuzzo, John Souglakos, Dalia Ercan, Andrew M. Rogers, Massimo Roncalli, Masayuki Takeda, Yasuhito Fujisaka, Juliet Philips, Toshio Shimizu, Osamu Maenishi, Yong Gon Cho, Jason Sun, Annarita Destro, Koichi Taira, Koji Takeda, Takafumi Okabe, Jeffrey Swanson, Hiroyuki Itoh, Minoru Takada, Eugene Lifshits, Kiyotaka Okuno, Jeffrey A. Engelman, Ramesh A. Shivdasani, Kazuto Nishio, Masahiro Fukuoka, Marileila Varella‐Garcia, Kazuhiko Nakagawa, Pasi A. Jänne - Science Translational Medicine 2011 cited by 670

  20. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

    Authors: Howard West, Mark L. McCleland, Federico Cappuzzo, Martin Reck, Tony Mok, Robert M. Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David S. Shames, Meghna Das Thakur, Geetha Shankar, Mark A. Socinski - Journal for ImmunoTherapy of Cancer 2022 cited by 151

  21. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    Authors: Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, Se‐Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji‐Youn Han, Mariam P. Alexander, Rohit Joshi, Enriqueta Felip, Pei Jye Voon, Pongwut Danchaivijitr, Ping‐Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K. Sabari, Angel Qin, Dariusz M. Kowalski, Mehmet Alı Nahıt Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish‐Berhane, Pamela L. Clemens, Patricia Lorenzini, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro, for the PALOMA-3 Investigators, Hiroaki Akamatsu, Mariam P. Alexander, Annalen Bleckmann, Federico Cappuzzo, Ying Cheng, Byoung Chul Cho, Timuçin Çil, Alexis B. Cortot, Pongwut Danchaivijitr, Till‐Oliver Emde, Dilek Erdem, Enriqueta Felip, F. Estevinho, Maria Lurdes Ferreira, Flavio Ferreira da Silva, Maria Campelo, Laurent Greillier, Alastair Greystoke, Ji‐Youn Han, Ping‐Chih Hsu, Jen‐Yu Hung, Mei Ji, Thomas John, Rohit Joshi, Young‐Chul Kim, Masashi Kondo, Ernesto Korbenfeld, Dariusz M. Kowalski, Se‐Hoon Lee, Natasha B. Leighl, Juan Li, Sheng-Hao Lin, Baogang Liu, Caigang Liu, John Seng-Hooi Low, Melina E. Marmarelis, Bartomeu Massutí, Anna R. Minchom, Sara Moore, Mor Moskovitz, Adnan Nagrial, Danny Nguyen, Silvia Novello, Y. Ohe, Mustafa Özgüroğlu, Özgür Özyılkan, Antonio Passaro, Nir Peled, Naiyarat Prasongsook, Angel Qin, Elisa F. Ramos and 22 more - Journal of Clinical Oncology 2024 cited by 114

  22. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Authors: Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam - The Lancet Oncology 2015 cited by 1,429

  23. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    Authors: Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip, Richard D. Hall, Óscar Juan, Daniel Brungs, Shun Lü, Marina Chiara Garassino, Michael Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron Lisberg, Jacob Sands, for the TROPION-Lung01 Trial Investigators, Gastón Lucas Martinengo, Juan Puig, Daniel Brungs, Bo Gao, Adnan Nagria, Christos S. Karapetis, Sagun Parakh, Cheol Park, Gaëtan Catala, Frédéric Forget, Sebahat Ocak, Naveen S. Basappa, Geoffrey Liu, Ines B. Menjak, Benjamin Shieh, Shun Lü, Feng Luo, Hongmei Sun, Jialei Wang, Yu Yao, Milada Zemanová, Jaafar Bennouna, Nicolas Girard, Laurent Greillier, Corinne Lamour, H. Léna, Céline Mascaux, Julien Mazières, Denis Moro‐Sibilot, M. Pérol, Elvire Pons‐Tostivint, Virginie Westeel, Akin Atmaca, Christine Greil, Niels Reinmuth, Christian Schumann, Thomas Wehler, Juergen Wolf, James Ho, Csaba Böcskei, Federico Cappuzzo, Filippo de Marinis, Claudia Proto, Manlio Mencoboni, Silvia Novello, Stefania Salvagni, Héctor Soto Parrà, Haruko Daga, Yasushi Goto, Hidetoshi Hayashi, Satoru Kitazono, Kiyotaka Yoh, Ryo Ko, Masashi Kondo, Toshiyuki Kozuki, Takayasu Kurata, Hideaki Mizutani, Kadoaki Ohashi, Satoshi Oizumi, Isamu Okamoto, Satoshi Sakaguchi, H Ozasa, Shunichi Sugawara, Yuichi Tambo, Motohiro Tamiya, Hiroshi Tanaka, Isamu Okamoto, Froylán López-López, Francisco Javier Ramírez Godinez, Jerónimo Rafael Rodríguez Cid, Robin Cornelissen, Steven Gans and 61 more - Journal of Clinical Oncology 2024 cited by 182

  24. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Authors: Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Craig H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, V. Gutiérrez Calderón, Melissa L. Johnson, Anne Madroszyk, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Ronald Shazer, Xin Yan, Richard Harrigan, Solange Peters, Isam Abdel-Karim, Mahmoud Abdelsalam, Alfredo Addeo, Carlos Aguado, Patrick Alexander, Jürgen Alt, Georges Azzi, Rama Balaraman, Bonne Biesma, Fiona Blackhall, Sabine Bohnet, Ekaterini Boleti, Hossein Borghaei, Penelope A. Bradbury, Matteo Brighenti, Nicholas Campbell, Toby Campbell, Jean-Luc Canon, Federico Cappuzzo, Enric Carcereny Costa, Luigi Cavanna, Jeremy Cetnar, Antonio Chella, C. Chouaïd, Daniel C. Christoph, J. Cortés Castán, Shaker R. Dakhil, F.J. de Castro Carpeño, Filippo de Marinis, Angelo Delmonte, Ingel Demedts, Wim Demey, Joyce Dits, Maria del Pilar Diz Taín, M. Dómine Gómez, Timothy Dorius, Daphne W. Dumoulin, M. Duruisseaux, Keith D. Eaton, Emilio Esteban González, Devon Evans, Martin Faehling, Nicholas Farrell, Trevor Feinstein, E. Felip Font, M.R. García Campelo, Edward B. Garon, María Pilar Garrido López, Paul Germonpré, Todd Gersten, María González Cao, Srivalli Gopaluni, Laurent Greillier, Francesco Grossi, Florian Guisier, Sarada Gurubhagavatula, Vanesa Gutiérrez Calderón, David Hakimian, Richard D. Hall, Desirée Hao, Ronald Harris, Sayed M.S. Hashemi, Kai He, Lizza Hendriks, Chao Huang, Emad Ibrahim, Sharad Jain, Melissa L. Johnson, B. J. P. Jones, Monte Jones, Óscar Juan, Rosalyn A. Juergens, Courèche Kaderbhaï, Elisabeth A. Kastelijn, Roger Keresztes, Ebenezer A. Kio, Konrad Kokowski, Kartik Konduri, Swati Kulkarni, Jonas Kuon and 84 more - Annals of Oncology 2023 cited by 93